<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177395</url>
  </required_header>
  <id_info>
    <org_study_id>PP100-001</org_study_id>
    <nct_id>NCT03177395</nct_id>
  </id_info>
  <brief_title>PP100-01 (Calmangafodipir) for Overdose of Paracetamol</brief_title>
  <acronym>POP</acronym>
  <official_title>A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PledPharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PledPharma AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety and tolerability of PP100-01 add-on treatment to the 12hr NAC
      treatment regime in patients treated for paracetamol/acetaminophen overdose (POD) when NAC
      treatment is initiated before 24hours post POD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be an open label, randomised, exploratory, rising dose design, NAC controlled,
      phase 1 safety and tolerability study in patients treated with NAC for
      paracetamol/acetaminophen overdose.

      Entry into the study will depend on the patient's blood results confirming the need for NAC.
      A total of 24 patients will be assigned into one of 3 dosing cohorts of 8 patients (N=6 for
      PP100-01 and NAC; N=2 for NAC alone).

      The study will primarily evaluate safety and tolerability for treatment with PP100-01 in
      combination with NAC as compared to NAC alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2017</start_date>
  <completion_date type="Actual">November 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Events</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse Events and Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT(U/L)</measure>
    <time_frame>Baseline</time_frame>
    <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT(U/L)</measure>
    <time_frame>10 hours</time_frame>
    <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT(U/L)</measure>
    <time_frame>20 hours</time_frame>
    <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>Baseline</time_frame>
    <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>10 hours</time_frame>
    <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>20 hours</time_frame>
    <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>value at 20 hours divided by baseline value for each patient</time_frame>
    <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional NAC Infusion</measure>
    <time_frame>Additional NAC at 12 hour</time_frame>
    <description>participants required additional NAC infusions after the 12-hour NAC regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K18 (U/L)</measure>
    <time_frame>Baseline (2 hours)</time_frame>
    <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K18(U/L)</measure>
    <time_frame>10 hours</time_frame>
    <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K18 (U/L)</measure>
    <time_frame>20 hours</time_frame>
    <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K18 (U/L)</measure>
    <time_frame>Ratio - value at 20 hours divided by baseline value for each patient</time_frame>
    <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ccK18 (U/L)</measure>
    <time_frame>Baseline (2 hours)</time_frame>
    <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ccK18 (U/L)</measure>
    <time_frame>10 hours</time_frame>
    <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ccK18 (U/L)</measure>
    <time_frame>20 hours</time_frame>
    <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ccK18 (U/L)</measure>
    <time_frame>Ratio - value at 20 hours divided by baseline value for each patient</time_frame>
    <description>Caspace-cleaved Keratin-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR-122 (Delta Count)</measure>
    <time_frame>Baseline (2 hours)</time_frame>
    <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR-122 (Delta Count)</measure>
    <time_frame>10 hours</time_frame>
    <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR-122 (Delta Count)</measure>
    <time_frame>20 hours</time_frame>
    <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR-122 (Copies/mcL)</measure>
    <time_frame>Baseline (2 h)</time_frame>
    <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR-122(Copies/mcL)</measure>
    <time_frame>10 hours</time_frame>
    <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR-122 (Copies/mcL)</measure>
    <time_frame>20 hours</time_frame>
    <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR-122 (Copies/mcL)</measure>
    <time_frame>Ratio - value at 20 hours divided by baseline value for each patient</time_frame>
    <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Paracetamol Overdose</condition>
  <arm_group>
    <arm_group_label>Acetylcysteine (N-acetylcysteine; NAC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PP100-01 (Calmangafodipir)+ NAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
Group A: PP100-01 (2 umol/kg calmangafodipir) after the &quot;loading&quot; dose of NAC
Group B: PP100-01 (5 umol/kg calmangafodipir) after the &quot;loading&quot; dose of NAC
Group C: PP100-01 (10 umol/kg calmangafodipir) after the &quot;loading&quot; dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP100-01 (calmangafodipir)</intervention_name>
    <description>PP100-01</description>
    <arm_group_label>PP100-01 (Calmangafodipir)+ NAC</arm_group_label>
    <other_name>PP100-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcysteine</intervention_name>
    <description>NAC</description>
    <arm_group_label>PP100-01 (Calmangafodipir)+ NAC</arm_group_label>
    <other_name>N-acetylcysteine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient with capacity admitted to hospital within 24 hrs either a single acute POD
             or more than one dose of paracetamol (staggered) and deemed to require treatment with
             NAC.

          2. Provision of written informed consent

          3. Males and females of at least 16 years of age

        Exclusion Criteria:

          1. Patients that do not have the capacity to consent to participate in the study

          2. Patients detained under the Mental Health Act or deemed unfit by the Investigator to
             participate due to mental health.

          3. Patients with known permanent cognitive impairment

          4. Patients who are pregnant or nursing

          5. Patients who have previously participated in the study

          6. Unreliable history of POD

          7. Patients presenting after 24hrs of POD

          8. Patients who take anticoagulants (e.g. warfarin) therapeutically or have taken an
             overdose of anticoagulants

          9. Patients who, in the opinion of the responsible clinician/nurse, are unlikely to
             complete the full course of NAC e.g. expressing wish to self-discharge

         10. Prisoners

         11. Non-English speaking patients. (Study information material will only be produced in
             English in view of the known and stable demographic of the Edinburgh self-harm
             population).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Dear</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>City Of Edinburgh</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <results_first_submitted>July 30, 2019</results_first_submitted>
  <results_first_submitted_qc>September 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2019</results_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03177395/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03177395/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Studied period: 05 June 2017 to 08 August 2018 Study centres: Edinburgh Clinical Trials Unit (ECTU) The Emergency Medicine Research Group Edinburgh (EMERGE)</recruitment_details>
      <pre_assignment_details>Adults within 24 h of a paracetamol overdose that required NAC. Within each of 3 sequential cohorts, participants were randomly assigned, with concealed allocation, to NAC and a single intravenous calmangafodipir dose (n=6/dose) or NAC alone (n=2). Calmangafodipir doses were 2, 5, or 10 μmol/kg. Participants, study and clinical teams not blinded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
          <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
        </group>
        <group group_id="P2">
          <title>Group A: PP100-01 (Calmangafodipir 2 μmol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 μmol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.</description>
        </group>
        <group group_id="P3">
          <title>Group B: PP100-01 (Calmangafodipir 5 μmol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 μmol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.</description>
        </group>
        <group group_id="P4">
          <title>Group C: PP100-01 (Calmangafodipir 10 μmol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (10 μmol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 24 participants randomised to the study. All participants received the full dose of PP100-01 according to the allocated dosing cohort where randomised to PP100-01 treatment and all participants received as a minimum 12 hours of NAC treatment (loading dose, plus further 10 hours). Total dose was adjusted according to participant weight</population>
      <group_list>
        <group group_id="B1">
          <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
          <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
        </group>
        <group group_id="B2">
          <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
        </group>
        <group group_id="B3">
          <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
        </group>
        <group group_id="B4">
          <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
• Group B: PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="12.5"/>
                    <measurement group_id="B2" value="42.5" spread="13.1"/>
                    <measurement group_id="B3" value="42.7" spread="12.7"/>
                    <measurement group_id="B4" value="22.7" spread="3.3"/>
                    <measurement group_id="B5" value="35.0" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from ingestion of paracetamol to hospital presentation</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="6.2"/>
                    <measurement group_id="B2" value="6.0" spread="6.2"/>
                    <measurement group_id="B3" value="5.8" spread="7.2"/>
                    <measurement group_id="B4" value="4.9" spread="5.2"/>
                    <measurement group_id="B5" value="6.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of overdose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Acute, ≤8 h to NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute, &gt;8 h to NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staggered intentional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supra-therapeutic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presentation paracetamol concentration</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" spread="81"/>
                    <measurement group_id="B2" value="127" spread="90"/>
                    <measurement group_id="B3" value="74" spread="44"/>
                    <measurement group_id="B4" value="127" spread="47"/>
                    <measurement group_id="B5" value="101" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total paracetamol ingested</title>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185" spread="156"/>
                    <measurement group_id="B2" value="235" spread="77"/>
                    <measurement group_id="B3" value="229" spread="72"/>
                    <measurement group_id="B4" value="397" spread="476"/>
                    <measurement group_id="B5" value="262" spread="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from ingestion of paracetamol to start of NAC treatment</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="5.2"/>
                    <measurement group_id="B2" value="9.8" spread="6.5"/>
                    <measurement group_id="B3" value="10.2" spread="6.9"/>
                    <measurement group_id="B4" value="8.6" spread="4.1"/>
                    <measurement group_id="B5" value="10.2" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from ingestion of paracetamol to start of calmangafodipir</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" spread="NA">No IMP given</measurement>
                    <measurement group_id="B2" value="12.6" spread="6.8"/>
                    <measurement group_id="B3" value="10.8" spread="4.1"/>
                    <measurement group_id="B4" value="11.8" spread="5.4"/>
                    <measurement group_id="B5" value="11.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any other drug ingested</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.7" spread="11.0"/>
                    <measurement group_id="B2" value="67.5" spread="13.3"/>
                    <measurement group_id="B3" value="67.3" spread="17.2"/>
                    <measurement group_id="B4" value="69.5" spread="13.1"/>
                    <measurement group_id="B5" value="69.8" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Events</title>
        <description>Adverse Events and Serious Adverse Events</description>
        <time_frame>90 days</time_frame>
        <population>In addition to paracetamol overdose, 19 out of the 24 randomised participants reported taking overdoses of other medicines in addition to the paracetamol. All treatment groups included participants with paracetamol only overdoses and mixed overdoses</population>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
Group A: PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
Group C: PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Events</title>
          <description>Adverse Events and Serious Adverse Events</description>
          <population>In addition to paracetamol overdose, 19 out of the 24 randomised participants reported taking overdoses of other medicines in addition to the paracetamol. All treatment groups included participants with paracetamol only overdoses and mixed overdoses</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event after commencement of NAC treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE after commencement of NAC treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event where outcome was death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event unrelated to NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event possibly related to NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event probably related to NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event definitely related to NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event unrelated to PP100-01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event possibly related to PP100-01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event probably related to PP100-01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event definitely related to PP100-01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any suspected unexpected serious adverse reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUSAR to NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUSAR to PP100-01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUSAR to NAC and PP100-01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT(U/L)</title>
        <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>ALT(U/L)</title>
          <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="3.6"/>
                    <measurement group_id="O2" value="24.6" spread="2.1"/>
                    <measurement group_id="O3" value="29.4" spread="2.3"/>
                    <measurement group_id="O4" value="17.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT(U/L)</title>
        <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
        <time_frame>10 hours</time_frame>
        <population>All 24 participants received the full dose of PP100-01 according to the allocated dosing cohort, all participants received as a minimum 12 hours of NAC treatment (loading dose, plus further 10 hours). For both PP100-01 and NAC total dose was adjusted according to participant weight</population>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>ALT(U/L)</title>
          <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
          <population>All 24 participants received the full dose of PP100-01 according to the allocated dosing cohort, all participants received as a minimum 12 hours of NAC treatment (loading dose, plus further 10 hours). For both PP100-01 and NAC total dose was adjusted according to participant weight</population>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="3.3"/>
                    <measurement group_id="O2" value="22.9" spread="1.8"/>
                    <measurement group_id="O3" value="25.3" spread="2.1"/>
                    <measurement group_id="O4" value="15.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT(U/L)</title>
        <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
        <time_frame>20 hours</time_frame>
        <population>All 24 participants received the full dose of PP100-01 according to the allocated dosing cohort, all participants received as a minimum 12 hours of NAC treatment (loading dose, plus further 10 hours). For both PP100-01 and NAC total dose was adjusted according to participant weight</population>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>ALT(U/L)</title>
          <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage.</description>
          <population>All 24 participants received the full dose of PP100-01 according to the allocated dosing cohort, all participants received as a minimum 12 hours of NAC treatment (loading dose, plus further 10 hours). For both PP100-01 and NAC total dose was adjusted according to participant weight</population>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="3.8"/>
                    <measurement group_id="O2" value="20.4" spread="1.9"/>
                    <measurement group_id="O3" value="25.4" spread="1.8"/>
                    <measurement group_id="O4" value="16.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INR</title>
        <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
        <time_frame>Baseline</time_frame>
        <population>All 24 participants received the full dose of PP100-01 according to the allocated dosing cohort, all participants received as a minimum 12 hours of NAC treatment (loading dose, plus further 10 hours). For both PP100-01 and NAC total dose was adjusted according to participant weight</population>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>INR</title>
          <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
          <population>All 24 participants received the full dose of PP100-01 according to the allocated dosing cohort, all participants received as a minimum 12 hours of NAC treatment (loading dose, plus further 10 hours). For both PP100-01 and NAC total dose was adjusted according to participant weight</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.04"/>
                    <measurement group_id="O2" value="1.00" spread="0.12"/>
                    <measurement group_id="O3" value="0.98" spread="0.04"/>
                    <measurement group_id="O4" value="1.05" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INR</title>
        <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
        <time_frame>10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>INR</title>
          <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.18"/>
                    <measurement group_id="O2" value="1.17" spread="0.20"/>
                    <measurement group_id="O3" value="1.20" spread="0.00"/>
                    <measurement group_id="O4" value="1.22" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INR</title>
        <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>INR</title>
          <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.21"/>
                    <measurement group_id="O2" value="1.07" spread="0.19"/>
                    <measurement group_id="O3" value="1.08" spread="0.04"/>
                    <measurement group_id="O4" value="1.22" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INR</title>
        <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
        <time_frame>value at 20 hours divided by baseline value for each patient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>INR</title>
          <description>international normalised ratio (INR) characterise acute liver injury (ALI) and failure (ALF)</description>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.17"/>
                    <measurement group_id="O2" value="1.07" spread="1.12"/>
                    <measurement group_id="O3" value="1.10" spread="1.07"/>
                    <measurement group_id="O4" value="1.10" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional NAC Infusion</title>
        <description>participants required additional NAC infusions after the 12-hour NAC regimen</description>
        <time_frame>Additional NAC at 12 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>Additional NAC Infusion</title>
          <description>participants required additional NAC infusions after the 12-hour NAC regimen</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>K18 (U/L)</title>
        <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
        <time_frame>Baseline (2 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>K18 (U/L)</title>
          <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" spread="2.20"/>
                    <measurement group_id="O2" value="177" spread="1.82"/>
                    <measurement group_id="O3" value="193" spread="1.56"/>
                    <measurement group_id="O4" value="128" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>K18(U/L)</title>
        <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
        <time_frame>10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>K18(U/L)</title>
          <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182" spread="1.95"/>
                    <measurement group_id="O2" value="152" spread="1.56"/>
                    <measurement group_id="O3" value="170" spread="1.42"/>
                    <measurement group_id="O4" value="111" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>K18 (U/L)</title>
        <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>K18 (U/L)</title>
          <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347" spread="3.18"/>
                    <measurement group_id="O2" value="229" spread="1.94"/>
                    <measurement group_id="O3" value="172" spread="1.45"/>
                    <measurement group_id="O4" value="181" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>K18 (U/L)</title>
        <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
        <time_frame>Ratio - value at 20 hours divided by baseline value for each patient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>K18 (U/L)</title>
          <description>In paracetamol overdose, the full-length variant of Keratin-18 (K-18) is released by necrotic hepatocyte death.</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="1.47"/>
                    <measurement group_id="O2" value="1.29" spread="1.89"/>
                    <measurement group_id="O3" value="0.89" spread="1.57"/>
                    <measurement group_id="O4" value="1.41" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ccK18 (U/L)</title>
        <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
        <time_frame>Baseline (2 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>ccK18 (U/L)</title>
          <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" spread="1.99"/>
                    <measurement group_id="O2" value="45" spread="1.33"/>
                    <measurement group_id="O3" value="84" spread="1.80"/>
                    <measurement group_id="O4" value="104" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ccK18 (U/L)</title>
        <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
        <time_frame>10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>ccK18 (U/L)</title>
          <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="2.24"/>
                    <measurement group_id="O2" value="53" spread="1.25"/>
                    <measurement group_id="O3" value="56" spread="1.57"/>
                    <measurement group_id="O4" value="78" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ccK18 (U/L)</title>
        <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>ccK18 (U/L)</title>
          <description>The shorter, Caspase cleaved form of K-18 is released following hepatocyte apoptosis (programmed cell death).</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="3.34"/>
                    <measurement group_id="O2" value="66" spread="1.34"/>
                    <measurement group_id="O3" value="85" spread="1.62"/>
                    <measurement group_id="O4" value="111" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ccK18 (U/L)</title>
        <description>Caspace-cleaved Keratin-18</description>
        <time_frame>Ratio - value at 20 hours divided by baseline value for each patient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>ccK18 (U/L)</title>
          <description>Caspace-cleaved Keratin-18</description>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.77"/>
                    <measurement group_id="O2" value="1.49" spread="1.55"/>
                    <measurement group_id="O3" value="1.02" spread="1.79"/>
                    <measurement group_id="O4" value="1.08" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>miR-122 (Delta Count)</title>
        <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
        <time_frame>Baseline (2 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>miR-122 (Delta Count)</title>
          <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
          <units>DCt</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="3.36"/>
                    <measurement group_id="O2" value="5.85" spread="1.50"/>
                    <measurement group_id="O3" value="4.43" spread="3.92"/>
                    <measurement group_id="O4" value="8.73" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>miR-122 (Delta Count)</title>
        <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
        <time_frame>10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>miR-122 (Delta Count)</title>
          <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
          <units>DCt</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="3.86"/>
                    <measurement group_id="O2" value="6.14" spread="1.99"/>
                    <measurement group_id="O3" value="5.01" spread="3.36"/>
                    <measurement group_id="O4" value="9.00" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>miR-122 (Delta Count)</title>
        <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>miR-122 (Delta Count)</title>
          <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
          <units>DCt</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="3.97"/>
                    <measurement group_id="O2" value="7.12" spread="2.26"/>
                    <measurement group_id="O3" value="4.49" spread="2.93"/>
                    <measurement group_id="O4" value="8.44" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>miR-122 (Copies/mcL)</title>
        <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
        <time_frame>Baseline (2 h)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>miR-122 (Copies/mcL)</title>
          <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
          <units>copies/mcL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146,363" spread="11.7"/>
                    <measurement group_id="O2" value="116,749" spread="2.4"/>
                    <measurement group_id="O3" value="194,075" spread="13.5"/>
                    <measurement group_id="O4" value="36,051" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>miR-122(Copies/mcL)</title>
        <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
        <time_frame>10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>miR-122(Copies/mcL)</title>
          <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
          <units>copies/mcL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206,205" spread="13.0"/>
                    <measurement group_id="O2" value="109,882" spread="3.3"/>
                    <measurement group_id="O3" value="196,732" spread="9.4"/>
                    <measurement group_id="O4" value="37,066" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>miR-122 (Copies/mcL)</title>
        <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>miR-122 (Copies/mcL)</title>
          <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
          <units>copies/mcL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216,256" spread="10.8"/>
                    <measurement group_id="O2" value="57,664" spread="3.8"/>
                    <measurement group_id="O3" value="202,271" spread="7.7"/>
                    <measurement group_id="O4" value="40,745" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>miR-122 (Copies/mcL)</title>
        <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
        <time_frame>Ratio - value at 20 hours divided by baseline value for each patient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
            <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
          </group>
          <group group_id="O2">
            <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O3">
            <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
          <group group_id="O4">
            <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
            <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
          </group>
        </group_list>
        <measure>
          <title>miR-122 (Copies/mcL)</title>
          <description>MiR-122 is a biomarker specific for liver injury and fully conserved (translational) across in vitro models, in vivo models and humans. MiR-122 is an early marker for acute liver injury which predicts a rise in ALT activity following paracetamol overdose</description>
          <units>copies/mcL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="5.71"/>
                    <measurement group_id="O2" value="0.49" spread="1.98"/>
                    <measurement group_id="O3" value="1.04" spread="8.28"/>
                    <measurement group_id="O4" value="1.13" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events / adverse reactions were assessed at baseline, 2, 2.5, 10, 20 and 22 hours as well as ad hoc and as part of follow up. Following discharge, patients were followed up using their electronic records. AE data were collected 7, 30 and 90 days after randomisation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acetylcysteine (N-acetylcysteine; NAC)</title>
          <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
        </group>
        <group group_id="E2">
          <title>Group A: PP100-01 (Calmangafodipir 2 Umol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (2 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
        </group>
        <group group_id="E3">
          <title>Group B: PP100-01 (Calmangafodipir 5 Umol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
        </group>
        <group group_id="E4">
          <title>Group C: PP100-01 (Calmangafodipir 10 Umol/kg)+ NAC</title>
          <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
PP100-01 (5 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 (10 umol/kg calmangafodipir) after the “loading” dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.
PP100-01 (calmangafodipir): PP100-01</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac disorders</sub_title>
                <description>Chest tightnes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Nausea, vomiting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>depressive episode;, mental health crisis;mental health issue (11006)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <description>seizures</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>heart block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaethesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ntentional product misuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>substance abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiration abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr James Dear</name_or_title>
      <organization>Pharmacology, Therapeutics and Toxicology Unit, Centre for Cardiovascular Science, University of Edinburgh, UK</organization>
      <phone>+44(0)131 242 9214</phone>
      <email>james.dear@ed.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

